Vannucchi, G <br/><br/>
Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.  [electronic resource] 

 -  Clinical and experimental immunology  Sep 2010 
 - 436-43 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2249 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2249.2010.04191.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Autoantibodies--blood<br/>B-Lymphocytes--drug effects<br/>Calsequestrin--immunology<br/>Chemokine CXCL10--blood<br/>Cytokines--blood<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Graves Ophthalmopathy--blood<br/>Humans<br/>Immunity, Humoral--drug effects<br/>Immunologic Factors--therapeutic use<br/>Inflammation Mediators--blood<br/>Interleukin-6--blood<br/>Male<br/>Middle Aged<br/>Receptors, Interleukin-6--blood<br/>Receptors, Thyrotropin--immunology<br/>Rituximab<br/>T-Lymphocytes--drug effects<br/>Thyrotropin--blood